Literature DB >> 1384424

Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II): a possible inhibitor of virus-cell fusion.

H Nakashima1, M Masuda, T Murakami, Y Koyanagi, A Matsumoto, N Fujii, N Yamamoto.   

Abstract

More than 40 peptides associated with tachyplesin and polyphemusin, which are highly abundant in hemocyte debris of the horseshoe crabs Tachypleus tridentatus and Limulus polyphemus, were synthesized. Among these peptides, we found that a novel compound, which was called T22 ([Tyr-5,12, Lys-7]polyphemusin II), strongly inhibited the human immunodeficiency virus type 1 (HIV-1)-induced cytopathic effect and viral antigen expression. Its 50% effective concentration was 0.008 micrograms/ml, while its 50% cytotoxic concentration was 54 micrograms/ml. The anti-HIV activity of T22 was observed with several strains of HIV-1, including zidovudine-resistant strains, and with HIV-2 within the concentration range of 0.006 to 0.071 microgram/ml. T22 efficiently inhibited giant cell formation on the cocultivation of MOLT-4/HIV and MOLT-4 cells but modestly inhibited direct HIV binding. T22 did not inhibit reverse transcriptase activity. A time-of-addition study, which involved monitoring of the appearance of proviral DNA by using the polymerase chain reaction technique, found that T22 exerted its effect on a process, most probably virus-cell fusion or uncoating, immediately after virus adsorption.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1384424      PMCID: PMC190327          DOI: 10.1128/AAC.36.6.1249

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  Human immunodeficiency virus (HIV)-induced cell fusion: quantification and its application for the simple and rapid screening of anti-HIV substances in vitro.

Authors:  T S Tochikura; H Nakashima; A Tanabe; N Yamamoto
Journal:  Virology       Date:  1988-06       Impact factor: 3.616

2.  Sulfation of polysaccharides generates potent and selective inhibitors of human immunodeficiency virus infection and replication in vitro.

Authors:  H Nakashima; O Yoshida; T S Tochikura; T Yoshida; T Mimura; Y Kido; Y Motoki; Y Kaneko; T Uryu; N Yamamoto
Journal:  Jpn J Cancer Res       Date:  1987-11

3.  Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds.

Authors:  R Pauwels; J Balzarini; M Baba; R Snoeck; D Schols; P Herdewijn; J Desmyter; E De Clercq
Journal:  J Virol Methods       Date:  1988-08       Impact factor: 2.014

4.  HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.

Authors:  B A Larder; G Darby; D D Richman
Journal:  Science       Date:  1989-03-31       Impact factor: 47.728

5.  Effects of succinylated concanavalin A on infectivity and syncytial formation of human immunodeficiency virus.

Authors:  T Matsui; S Kobayashi; O Yoshida; S Ishii; Y Abe; N Yamamoto
Journal:  Med Microbiol Immunol       Date:  1990       Impact factor: 3.402

6.  Inhibitory effect of tachyplesin I on the proliferation of human immunodeficiency virus in vitro.

Authors:  M Morimoto; H Mori; T Otake; N Ueba; N Kunita; M Niwa; T Murakami; S Iwanaga
Journal:  Chemotherapy       Date:  1991       Impact factor: 2.544

7.  HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure.

Authors:  J A Zack; S J Arrigo; S R Weitsman; A S Go; A Haislip; I S Chen
Journal:  Cell       Date:  1990-04-20       Impact factor: 41.582

8.  3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.

Authors:  H Mitsuya; K J Weinhold; P A Furman; M H St Clair; S N Lehrman; R C Gallo; D Bolognesi; D W Barry; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

9.  Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro.

Authors:  M Baba; R Pauwels; J Balzarini; J Arnout; J Desmyter; E De Clercq
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

10.  Inhibition of replication and cytopathic effect of human T cell lymphotropic virus type III/lymphadenopathy-associated virus by 3'-azido-3'-deoxythymidine in vitro.

Authors:  H Nakashima; T Matsui; S Harada; N Kobayashi; A Matsuda; T Ueda; N Yamamoto
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

View more
  30 in total

Review 1.  Host defence (cationic) peptides: what is their future clinical potential?

Authors:  R E Hancock
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

2.  Skin mast cells protect mice against vaccinia virus by triggering mast cell receptor S1PR2 and releasing antimicrobial peptides.

Authors:  Zhenping Wang; Yuping Lai; Jamie J Bernard; Daniel T Macleod; Anna L Cogen; Bernard Moss; Anna Di Nardo
Journal:  J Immunol       Date:  2011-12-02       Impact factor: 5.422

Review 3.  Peptide antimicrobial agents.

Authors:  Håvard Jenssen; Pamela Hamill; Robert E W Hancock
Journal:  Clin Microbiol Rev       Date:  2006-07       Impact factor: 26.132

Review 4.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

5.  T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure.

Authors:  R Arakaki; H Tamamura; M Premanathan; K Kanbara; S Ramanan; K Mochizuki; M Baba; N Fujii; H Nakashima
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

6.  Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases.

Authors:  Chih-Hung Lee; Takashi Kakinuma; Julia Wang; Hong Zhang; Douglas C Palmer; Nicholas P Restifo; Sam T Hwang
Journal:  Mol Cancer Ther       Date:  2006-10       Impact factor: 6.261

7.  Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro.

Authors:  Jia Ma; Suzanne Kennedy-Stoskopf; Jesse M Jaynes; Linda M Thurmond; Wayne A Tompkins
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

Review 8.  Chemokine receptor CXCR4 as a therapeutic target for neuroectodermal tumors.

Authors:  Hyunsuk Shim; Shinya Oishi; Nobutaka Fujii
Journal:  Semin Cancer Biol       Date:  2008-11-25       Impact factor: 15.707

9.  The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.

Authors:  Tsutomu Murakami; Sei Kumakura; Toru Yamazaki; Reiko Tanaka; Makiko Hamatake; Kazu Okuma; Wei Huang; Jonathan Toma; Jun Komano; Mikiro Yanaka; Yuetsu Tanaka; Naoki Yamamoto
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

10.  Exploratory studies on development of the chemokine receptor CXCR4 antagonists toward downsizing.

Authors:  Hirokazu Tamamura; Hiroshi Tsutsumi; Wataru Nomura; Nobutaka Fujii
Journal:  Perspect Medicin Chem       Date:  2008-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.